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Abstract  
Background and purpose: Neo-adjuvant chemotherapy is recommended for ‘inoperable’ 
locally advanced and inflammatory breast cancers. For operable breast cancers, trials 
indicate no survival differences between chemotherapy given pre or post-surgery. 
Communicating evidence based information to patients is complex and studies examining 
patient experiences of neo-adjuvant chemotherapy are lacking. This study aims to explore 
the experiences of women who received neo-adjuvant chemotherapy for breast cancer. 
Methods: A qualitative approach using in-depth interviews with 20 women who had 
completed neo-adjuvant chemotherapy for breast cancer. Interview data were analysed 
using thematic analysis. 
Results: The sample included a relatively young group of women, with caring 
responsibilities. Five main themes emerged: coping with the rapid transition from ‘well’ to 
‘ill’, information needs and decision making, needing support and empathy, impact on 
family, and creating a new ‘normal’. More support was needed towards the end of 
chemotherapy, when side effects were at their most toxic, and decisions about forthcoming 
surgery were being made. Some women were referred to psychological services, but usually 
when a crisis point had been reached.        
Conclusion:  Information and support would have been beneficial at key time points. This 
information is vital in developing services and interventions to meet the complex needs of 
these patients and potentially prevent late referral to psychological services. Specialist 
oncology nurses are able to develop empathetic relationships with patients and have the 
experience, knowledge and skills to inform and support women experiencing neo-adjuvant 
chemotherapy. Targeting key time points and maintaining relationship throughout neo-
adjuvant chemotherapy would be highly beneficial.  
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Highlights 
 
 
 Communicating information to patients about neo-adjuvant chemotherapy is complex  
 Studies examining patient experiences of neo-adjuvant chemotherapy are lacking 
 
 This study explored patient  experiences and made recommendations for practice 
 
 Participants identified key times points when more information and support were required 
 
 Meeting needs can potentially prevent late referral to psychological services  
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Exploring patient experiences of neo-adjuvant chemotherapy for breast cancer  
 
BACKGROUND 
Chemotherapy has become a major cancer treatment modality, with increasingly toxic regimes 
aimed at improving outcomes (Del Mastro, Costantini, Morasso, Bonci, Bergaglio, Banducci et al 
2002). Side effects of chemotherapy are numerous and can be immediate (e.g. facial and bodily 
flushing, hypotension, abnormal tastes and smells), short term (e.g. nausea, vomiting, gastro-
intestinal disturbances, stomatitis) and long term (e.g. alopecia, renal toxicity, sexual dysfunction, 
fatigue) (Dougherty, Bailey 2008). Given the severity of side effects, patients are likely to have a 
number of concerns, many of which may not be identified by nurses (Farrell, Heaven, Beaver, 
Maguire 2005), with discrepancies between patient and health care professional (HCP) perceptions 
of priority concerns (Mulders, Vingerhoets, Breed 2008).   
 
While there is much literature on the physical side effects of chemotherapy, there is far less 
evidence on the psychosocial impact of chemotherapy.  Chemotherapy is distressing and can have a 
long term impact on quality of life (Ganz, Desmond, Leedham, Rowland, Meyerowitz, Belin 2002). 
Women undergoing chemotherapy have reported priority concerns relating to current illness, the 
future, inability to do things and physical symptoms (Farrell, Heaven, Beaver, Maguire 2005). For 
breast cancer survivors the most important issues in relation to the impact of cancer and 
chemotherapy have been reported as fear of metastases, fatigue, consciousness of one’s own 
vulnerability, hair loss and nausea (Mulders, Vingerhoets, Breed 2008). A qualitative study carried 
out in the UK with both male and female patients has shown that chemotherapy imposes drastic 
changes in social and emotional wellbeing as well as negative impacts on concentration and memory 
(Mitchell 2006). Mitchell (2013) reported on a desire to return to normality and regain control over 
life compounded by concerns over children. Although partners and spouses were reported as 
supportive, teenage children were described as unsupportive (Mitchell 2013).    
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For women diagnosed with breast cancer who require adjuvant treatment, it is usual to offer 
chemotherapy after surgery. However, chemotherapy can also be given prior to surgery. Neo-
adjuvant chemotherapy (also referred to as pre-operative chemotherapy or primary systemic 
therapy) is commonly recommended for locally advanced and inflammatory breast cancers; cancers 
often defined as inoperable with a poor prognosis (Chia, Swain, Byrd, Mankoff 2008). The 
advantages of neo-adjuvant therapy in locally advanced and inflammatory breast cancers include 
earlier treatment of subclinical micro metastases, downstaging of the primary tumour (which may 
allow an inoperable tumour to become operable) and the ability to assess response to therapy(Chia, 
Swain, Byrd, Mankoff 2008).  For some patients with locally advanced disease (but not inflammatory 
cancer) conservative surgery may emerge as a treatment option (Gralow, Burstein, Wood, 
Hortobagyi, Gianni, von Minckwitz 2008). A major disadvantage of pre-operative chemotherapy is 
the potential for considerable delay before surgery for patients whose tumours prove resistant to 
neo-adjuvant chemotherapy (Van der Hage, van de Velde, Mieog 2009). Neo-adjuvant 
chemotherapy for women with operable breast cancer is not clearly defined as yet although trials 
indicate no difference in survival between women treated pre or post-surgery (Van der Hage, van de 
Velde, Mieog 2009). 
 
Selecting patients for neo-adjuvant therapy and communicating evidence based information is 
clearly complex, particularly for women diagnosed with more aggressive and/or advanced cancers. It 
can be argued that surgery, cutting out the problem, is readily understood whereas systemic 
treatment is more complex to understand (Beaver, Jones, Susnerwala, Craven, Tomlinson,  
Witham et al 2005). It has been shown that breast care nurses (BCN) are an important source of 
information and support, helping women cope with their disease (Beaver, Tysver-Robinson, 
Campbell, Twomey, Williamson, Hindley et al 2009; Cruikshank, Kennedy, Lockhart, Dosser, Dallas 
2008,). However, for those women who receive neo-adjuvant treatment, it is not clear what their 
specific needs and concerns are and how services can best be organised to meet those needs. 
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Research is lacking on the specific needs, concerns and experiences of women who receive neo-
adjuvant chemotherapy for breast cancer. Understanding these could help to target information, 
psychological support and interventions more appropriately. In addition, there is little research on 
how best to enable the decision making process for women who are faced with choices about 
whether to have chemotherapy before or after surgery. An understanding of the important factors 
determining  patient preferences for different treatment  options would enable more effective 
interventions to be developed and evaluated that would assist the decision making process. 
However, if neo-adjuvant chemotherapy is required due to the size or type of tumour and there are 
no choices presented then it is important to examine how this information is conveyed to patients 
and whether they fully understand the rationale behind clinical decisions.  
 
OBJECTIVE 
This study aimed to explore the experiences of women who received neo-adjuvant chemotherapy 
for breast cancer to determine psycho-social, information and support needs.            
 
METHODS 
Qualitative methods are well suited to exploring subjects where little is known and for gaining new 
insights and fostering deeper understanding of particular phenomena (Morse & Richards 2002). As 
we could find no evidence of previous studies that examined the experiences of women with breast 
cancer who undergo neo-adjuvant chemotherapy, a qualitative study was justified as an initial 
exploratory step. We did not take a theoretically driven qualitative approach but chose a more 
generic approach as our intention was to focus more pragmatically on the clinical research question 
than the philosophical underpinnings. We acknowledge that there are interesting debates on 
theoretical versus generic approaches in qualitative research (Smith, Becker, Cheater 2011; 
Sandelowski 2000). We chose to use a qualitative descriptive approach as this involves remaining 
close to the data and is particularly suited to answering questions that have relevance for 
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practitioners and policy makers (Sandelowski, 2000). Individual in-depth interviews were chosen as 
the most suitable method for obtaining rich and detailed data, exploring individual personal 
perspectives to generate an in-depth understanding of the particular subject area (Ritchie & Lewis 
2006).   
 
Study Location 
Study participants were recruited from four hospitals across Lancashire and South Cumbria in the 
North West of England that served an estimated population of 1.6 million residents in diverse 
geographical areas, allowing for recruitment of participants who may have had different experiences 
in terms of service provision and support. 
 
Sample and Sample Size 
Women were identified as suitable to take part in the study if they had undergone neo-adjuvant 
chemotherapy for breast cancer between May 2012 and April 2013. To maximise women’s recall of 
events we did not recruit any individuals who were further than 12 months post chemotherapy. The 
number of interviews conducted was limited by study duration but was also guided by emergent 
findings and reaching a point at which no new information emerged. 
 
Access and Recruitment 
Ethical approval was obtained from the National Research Ethics Service in the UK and from the 
Research and Development departments at study sites. Specialist BCN’s at the study locations were 
asked to identify suitable participants who met the inclusion criteria and to contact eligible women, 
describing the study and inviting participation. Potential participants were offered contact from a 
researcher, who discussed the study further and provided information sheets, consent forms and 
postage paid reply envelopes (for return of consent forms). Potential participants were asked to 
return a signed consent form, after which a suitable date and time for interview was arranged.  
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Interviews 
In depth face-to-face interviews were carried out with participants by two researchers experienced 
in qualitative data collection and analysis. All interviews were audio-recorded and transcribed using 
a professional transcribing service. An interview guide was constructed for the study to address the 
following areas: how information and choices about chemotherapy were communicated; patients 
experiences of neo-adjuvant chemotherapy and the support needed; patient views on the delay to 
surgery; views on adequacy of service provision; any concerns experienced during treatment 
(physical, psychological, social); psychological distress and referrals to psychological support 
services; information needs: what information was needed, sources of information (Figure 1). In 
addition, socio-demographic and treatment information was requested from study participants to 
describe the sample and to look for any emerging patterns in the data that could indicate predictors 
of need that could be explored in future work.  
 
Data Collection 
Study participants all chose to be interviewed in their own homes. Participant confidentiality was 
protected through the use of code numbers and the removal of all identifying information (e.g. 
names of HCPs, names of hospitals) from the data transcripts.  
 
ANALYSIS 
Two researchers independently coded the interview data using manifest content analysis procedures 
(Graneheim & Lundman 2004, Morse & Field 1998). NVIVO (a software package for managing and 
organising qualitative data) was used to assist with data management. Transcripts were read and 
initially open coded to begin identification of themes and categories. Any discrepancies in coding 
were resolved through review of the data and discussion until consensus was reached. Measures 
were taken to ensure the rigour of the research process as recommended in qualitative research 
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(Denzin & Lincoln 2000), including line-by-line analysis and regular review and de-briefing involving 
both coders. All quantitative data were entered into the data entry component of SPSS v20 and 
descriptive statistics were used to describe the study sample in terms of socio-demographic (e.g. 
age, marital status) and disease/treatment details (e.g. time from diagnosis, type of treatment).  
 
FINDINGS 
Characteristics of the Study Sample  
Twenty women who had completed neo-adjuvant chemotherapy for breast cancer were interviewed 
across four different study locations. The mean age of the sample was 48 years, ranging from 30 to 
67 years, and 11 had school age children. Women were a mean of 15.5 months from initial diagnosis, 
ranging from eight to 27 months. Other socio-demographic and disease/treatment related 
characteristics are shown in Table 1. A typical participant was married, working full time and had 
formal qualifications. The majority (19/20, 95%) had undergone a mastectomy; three of these 
women had both breasts removed by choice (i.e. removal of affected breast and contralateral 
prophylactic mastectomy of the unaffected breast). Eleven women (55%) had required a hospital in-
patient admission during the course of their treatment, usually in association with side effects of 
chemotherapy treatment. Half the sample had received formal counselling, either for themselves or 
for their children.     
<Insert Table 1 here> 
 
Themes 
Five major themes emerged from the data: coping with the rapid transition from ‘well’ to ‘ill’, 
information needs and decision making, needing support and empathy, impact on family and 
creating a new ‘normal’.  
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Coping with the rapid transition from ‘well’ to ‘ill’ 
Participants had to live with the knowledge that the cancer was still present throughout treatment 
and, while they reported that the intention of the chemotherapy was to shrink the tumour, there 
were anxieties expressed about knowing that the cancer remained in their body.  
 
 ‘It was hard for me to bring the lump home and sleep with it and shower it’ (ID 17)  
 
‘…there’s always sort of hidden worries in there that whilst they’re not actually taking the 
tumour away, then you’re wondering whether it’s getting bigger or what’s happening to it, 
whether it’s spreading or whatever, you know.’ (ID 19) 
 
 
Once chemotherapy commenced there was a rapid transition from being fit and healthy, having a 
full/part time job balanced with caring for young children and/or elderly parents to being ‘ill’ but 
retaining all the responsibilities associated with employment and parenthood.  Neo-adjuvant 
chemotherapy was reported as an ‘awful’, ‘frightening’, ‘horrendous’ experience. Women felt 
unprepared for the immediacy of side effects (e.g. total hair and nail loss, oral mucositis, fatigue), 
while still dealing with the shock of the cancer diagnosis. Eleven women were admitted to hospital 
requiring treatment for chemotherapy side effects; four felt that they could not emotionally or 
physically continue with treatment and two reported that they refused to continue with 
chemotherapy and insisted on surgery. Enduring the final cycle of chemotherapy was a particularly 
difficult time; side effects had become extreme and women wanted it to be over but surgery still lay 
ahead.  One woman described her treatment for breast cancer (neo-adjuvant chemotherapy, 
surgery and radiotherapy) as ‘being poisoned, burnt and mutilated. You know it’s medieval torture 
with a twist’ (ID 16).  
  
‘I just thought, I just got to that point, no more.  I don't want it anymore...  I got to that point 
where I just…no, that’s it, cut it out now.’ (ID 15) 
 
The women admitted to hospital had found the experience traumatic, reporting that they were 
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being treated by generalist clinicians with little specialist cancer and/or chemotherapy knowledge. 
Participants tended to be admitted to general medical wards, via emergency departments, where 
staff did not understand their particular needs and were not able to respond appropriately.  
 
‘So I spent perhaps a week in the hospital.  But was a bit… alone… because the hospital didn’t 
know what they were doing because you get all these different doctors in the hospital and 
there’s not one set.  I had blisters in my mouth and everything...I kept saying, “I can’t 
swallow, it’s hurting.”  And they just kept saying, “Oh well, you’ll be fine.  You know, it’s just 
normal.”  And I'm thinking....  Yeah, I know it’s probably normal but.... They gave me 
antibiotics in tablet form which I couldn’t swallow, the nurse kept putting “Refused to take 
medication” which I wasn’t refusing.  It’s just that I couldn’t swallow any medication at all.’ 
(ID 13) 
 
The impact of chemotherapy on cognitive function was referred to by five women as ‘chemo brain’. 
They perceived this was not formally recognised as a condition, especially by oncologists, although 
BCN’s were more likely to acknowledge the existence of ‘chemo brain’.  
  
‘When I ask about my chemo brain to my consultant, the answer is, “Oh it’s just subjective.  It 
doesn’t exist.”  And you know there is no point discussing it any further because all the 
information is all anecdotal. … I couldn’t remember the name of Shakespeare’s wife for 
goodness sake, I am an English teacher.  I, you know I couldn’t believe it, it was unbelievable. 
It was terrifying actually.’(ID 03) 
 
‘In fact I even gave up driving the car because I was…it was obvious to me that I wasn’t on 
top of it as usual…I just wasn’t… there was like a sort of fog in your mind which you….  And 
nobody prepared me for that at all, that aspect of it.’ (ID 19) 
 
Many participants had to continue their role as a mother to young children and attempt to continue 
working while undergoing chemotherapy and this may have added an additional burden to the 
negative experience.  
 
‘Oh god, I really am really poorly. Because you’re floating along getting all the information 
off different people, and then the physical side of things happens.  And that’s when it sinks in, 
because you’re seeing it….You see, I was perfectly healthy before.  I used to go in the gym.  I 
used to go outside climbing, swimming.  And then, these things start falling off and it’s like, 
“Oh, right.  Now I’m ill.”  I wasn’t ill, you know, not knowingly ill before, but now …’ (ID 11)   
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There was a reluctance to get in touch with HCPs about problems as this could often mean travelling 
long distances to a specialist centre at a time when they felt too ill to travel. At this time participants 
would have welcomed a home visit or telephone contact.  
 
‘Or maybe even a home visit, you know.  If you could make a phone call and say, “I am 
feeling dreadful, I’ve got this, this, and this,” you don’t want them to say, “Oh, come to 
[name of hospital].”  It would be great if they could say, “Well, we have a community nurse 
who deals with this”.’ (ID 12) 
 
Information needs and decision making 
The initial, and unexpected, shock of diagnosis was disabling in terms of retaining and recalling 
information about treatment plans and side effects. Participants reported being given information at 
diagnosis but perceived that there were few further opportunities to ask questions, seek clarification 
or have information repeated. Most participants had met a BCN at the time of their diagnosis but 
this contact was then usually severed until chemotherapy had been completed; this could be many 
months later. Although participants commented that they needed more information about 
chemotherapy, it was acknowledged that it was difficult to know what information was needed until 
an individual had been through the experience. Not all participants wanted full information as they 
perceived this as potentially frightening. There were anxieties about asking questions in case the 
answer included yet more bad news.  
‘you’re absorbing so little of some very important information.  …I knew I could pick up the 
phone but maybe it was one of those things well, they’re busy, you know… I don’t think you 
want bad news actually. You’ve heard enough.’ (ID 12) 
 
Participants understood that chemotherapy was being prescribed prior to surgery in order to shrink 
the tumour. Given this rationale it was difficult to understand why the whole breast was removed. 
Few indicated an understanding that chemotherapy was a systemic treatment. Participants reported 
receiving conflicting information from different HCP’s and struggled to make sense of the overall 
treatment plan.   
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‘I mean they said that they wanted to reduce the size of the tumour. Fair enough. But in fact, 
it didn’t make any difference, whether it was reduced or not, because they still did the same 
operation that they’d intended to do.’ (ID 19)   
 
Once chemotherapy had commenced, participants reported that it was challenging to obtain 
information. Chemotherapy nurses were knowledgeable about chemotherapy but the busyness of 
chemotherapy units was not conducive to asking questions. Community nurses were mentioned as 
being helpful and supportive but lacked information on side effects of treatment. Follow-up 
appointments with oncologists, and later with surgeons, were perceived as rushed with few 
opportunities to ask questions or seek clarification.    
 
‘When you go for an appointment at that stage, you see the consultants and to be quite 
honest he breezes  through the door on one side and goes out the door at the other side, he 
barely stops in between, you know.    … he’s really good but you don’t have a chance to talk 
to him. So, then you got to grab the nurse but the trouble is he’s then off to the next one and 
she’s supposed to go with him.   … So, you feel like when you’re actually there at an 
appointment, you don’t get the chance to chat.  And then that means that you’ve either then 
got to try and phone up and have a chat which sometimes is very difficult.’ (ID 05) 
 
Although participants had been given telephone numbers for the breast care nursing service and the 
chemotherapy unit and had been instructed to call if they were concerned or had queries, they were 
not sure whether what they were experiencing was ‘normal’ or which number they should call in a 
given circumstance. 
 
‘This was the very first session it [severe vomiting and mucositis] happened, so we weren’t 
sure who to go to, do you know what I mean?  Like if...because I had been going to my GP 
[General Practitioner] or go to chemo depart-...ring chemo department, would you ring? 
Would you...?  We weren’t sure about everything and then after that, he [husband] rang the 
breast care nurse.’ (ID 13) 
 
Other sources of information mentioned by participants included written information provided by 
HCP’s, Internet sources and videos/DVD’s that were watched in chemotherapy units. Although 
participants recalled being provided with written information, many reported that they did not read 
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it or could not absorb it. However, it could be useful for family members or to refer to at a later date. 
Participants searched for information on the Internet but this was generally perceived as being 
frightening and anxiety provoking. However, on-line forums could be reassuring for some patients, 
especially in respect of finding out if particular symptoms were ‘normal’.  
 
‘I was looking at the pile of literature that they give you. And I just thought that was...No, I 
don't want to look at it because I haven't got it. You know, it's like denial, I suppose. … Well, I 
got talking to other people (on line). So, you kind of knew what to expect, and what was the 
norm, really. So, you knew that if you had certain symptoms, that other people would have 
these symptoms as well. So, it was really quite normal to be like that. So, that was 
reassuring.’ (ID 20) 
 
Only two participants reported being involved in the decision making process about whether to have 
chemotherapy before or after surgery. All remaining participants perceived that there had been no 
choice offered and accepted that chemotherapy would be given prior to surgery. Participants placed 
their trust in doctors to make the right decision, in the patients’ best interests. Even if participants 
did not fully understand the treatment plan, they did not question it as they placed their trust in 
HCP’s and perceived that they should do as they were told. 
 
‘But it's very, it's very difficult because obviously you tell other people, your family. And their 
reaction is, the same as ours is, why are you not going to chop it off, why are you going to 
send me home with my lump? . They know what they're doing, I don't. And I have to trust 
these people who are going to treat me. So, I didn't question. I didn't ask a single question 
until I was in about my fifth or sixth treatment of chemo, which was months down the line. I 
just turned up and did as I was told.’ (ID 17) 
 
As the chemotherapy treatment took place over a relatively long period of time participants had 
time to think about forthcoming surgery. Participants attempted to be more assertive about 
treatment options related to surgery than to chemotherapy. However, few were presented with 
surgical options as mastectomy was deemed necessary for 19 of the 20 women. Six women wanted 
to have both breasts removed following chemotherapy (i.e removal of the affected breast and 
contralateral prophylactic mastectomy of the unaffected breast); three realised their preference 
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while two had one breast removed initially and secured agreement to have the remaining 
unaffected breast removed at a later date. Women who wanted both breasts removing had a clear 
rationale and did not want to risk recurrence of breast cancer and further surgery in the future. 
Participants reported that BCN’s were supportive of their preference but it was challenging to gain 
agreement from surgeons who were reluctant to remove healthy breast tissue; women had to take 
an assertive stance and did not always succeed. A referral to a clinical psychologist was required if 
women wanted to have both breasts removed.   
 
‘I don’t like to make bold statements but I know that had they said to me you're having the 
operation first, then chemo, then radiotherapy, I would only have had one (breast) removed. 
. …Having had the chemo first, the time it's taken to have that obviously gave me a chance to 
move through different phases of you know, how you feel and what you think … Initially, my 
thoughts were I don't want to die now with my children being young. So, do what you're told 
to do. So, I did that. Once I'd got a bit through the chemo and a little bit more sane, and I 
suppose it had sunk in and things were working.  I then thought, I stopped thinking about I 
don't want to die and I started thinking about how can I try and live.’ (ID 17)  
 
Needing support and empathy 
Participants expressed a need for support and empathy in relation to the physical and psychological 
impact of diagnosis and treatment. The most important sources of support reported were family 
members. Few participants perceived that they had received support from HCP’s while undergoing 
chemotherapy, especially in relation to psychological support. Only three participants mentioned 
attending face-to-face support groups, while one participant had accessed an on-line support group.  
Participants often reached crisis point before seeking support for the emotional impact of the 
diagnosis and treatment.  
‘I think right from the beginning.  I’m one of these people...I’m hugely independent.  Don’t 
like being trouble to anybody.  And I think somebody should have sat me down and said 
“look, I think you need some help”.  It got to the stage where it was really bad before I asked 
for it.  Maybe I should have asked for it sooner.’  (ID 08) 
 
Participants noticed that they were noticeably younger than  other patients undergoing 
chemotherapy  and wanted empathy and support from someone who would appreciate what they 
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were going through, from someone who had experienced chemotherapy and was relatively young 
with young children. 
 
 ‘There’s nothing like somebody who’s been through it, you know, who can help because they 
know.  … I know my chemo wasn’t any worse than anybody else’s in that room.  But I just 
look at them and they were old and I just think you can go home now … you can sit and relax 
for the rest of the night.  I have to go home and be mum and try and put a smile on my face 
and, you know, wipe bottoms or, you know, whatever … and you just don’t want to.  You do 
want to; you want to be mum, but it’s so, so exhausting.  And I really wanted somebody else 
to talk to who’d been through that and know what it was like to cope with two children and 
chemotherapy.’ (ID 06) 
 
Participants did not tend to receive support from other patients in a similar position as neo-adjuvant 
chemotherapy was not a common treatment. However, it was considered helpful to have someone 
to talk to who had also experienced chemotherapy prior to surgery, even if not for treatment of 
breast cancer.  
‘…a gentleman who actually had bowel cancer but he had chemo before surgery.  And his 
advice was probably the best because he told me exactly what each stage was going to be 
like.  And it was exactly as he said and he gave me advice on how to cope.  ’ (ID 10)   
 
Impact on family 
All participants commented on the importance of family for psychological support. The family unit 
was vital for providing support and seeking out explanations when participants initially felt unable to 
process the information they were being given. However, participants commented on their need to 
be strong, protecting young children, ageing parents and other family members from emotional pain 
or too much information that could be perceived as frightening and upsetting. This was challenging 
when faced with the physical and emotional burden of diagnosis and treatment. 
 
‘…my sister was visiting from America with the baby and it was the first time she’d been over.  
And I thought, I can’t tell them all what’s going on; I don’t want this visit clouded by what’s 
going on with me. …and it was my daughter’s birthday as well.  And I’m bringing out the 
birthday cake and I just, started crying. I’m thinking, my God. This could be the last birthday 
I’m ever going to see. And everybody said, “what’s the matter, what’s the matter?”  And I 
just go “I can’t tell you, I can’t tell you”.  And they all at that time thought it was because, 
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whatever it was that I couldn’t trust them with something.  And it wasn’t that. I just didn’t 
want to cloud... upset them. ’ (ID 09) 
 
Participants were aware that their family members needed support themselves as some of the side 
effects of chemotherapy could be frightening, especially for young children. Two participants had 
sought psychological help for their children after it was suggested by their children’s school 
teachers; this had been found to be beneficial. 
 
‘They’ve (children) been through too much already.  I fainted on the toilet once and she 
(daughter) was the one that found me.  So, you know, there was a time she didn’t want me 
to go to the toilet.  You know, they just…for little children, they’ve been through things that 
no children should have to go through.’ (ID 06) 
 
Although participants commented on the value of family support,  they also acknowledged the 
added responsibility of  trying to support family and care for young children and/or ageing parents 
while coping with diagnosis and treatment. Seeing the impact of the diagnosis and treatment on 
family members was painful for participants. None remembered receiving any help or support in 
how their role as a wife or a mother or a daughter might be affected or how they should break bad 
news to their children, husbands or parents. They knew their families would be upset but they had 
no framework for how to deal with their distress. 
 
‘So, I don’t think perhaps there was much support for him (husband).  I don’t think there was.  
Or if it was there, we never looked for it.  Maybe it’s there and we didn’t look for it.  I don’t 
know.  Maybe he’s…he was kind of always tagged on.  Looking back on it now, I feel quite 
sorry for him actually because he was more or less ignored all the way through it.  So even if I 
was speaking to a doctor or a nurse, (name of husband) was just there as a shadow. And I 
think actually, that’s not a bit, not fair really, is it?’  (ID 12) 
 
‘And then my son and he was only seventeen at that time, bless him, came to pick me up 
[from chemotherapy treatment] and I can remember seeing his face. And I just thought, I 
shouldn’t have put him through this.’ (ID 10)  
 
Creating a new ‘normal’ 
Participants reported that they had expected the side effects of chemotherapy to disappear once 
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treatment had been completed and were surprised that they would have to cope with long term 
complications such as neuropathy that would affect their day to day function. The majority of 
participants had returned to work at the time of interview. Employers were generally reported as 
being understanding during treatment but less so once treatment had been completed, mistakenly 
assuming the employee would quickly return to a pre-diagnosis state of health. 
 
‘I handed another sick note in and she (employer) said “well what’s the reason on it?”  And I 
said, “Treatment for breast cancer.”  And she said, “But you’re finished with treatment now.” 
Well, no, I haven’t thank you very much. So yeah I just felt like I was being pushed to go back 
in.  And then I got told that if I didn’t go back by a certain day, that was it. So I went back 
part time and that hasn’t been very good.’ (ID 01) 
 
Participants wanted to get back to ‘normal’ but acknowledged that being diagnosed and treated for 
cancer had a massive physical and emotional impact,  requiring a new normal  to be created. Aspects 
of normality involved returning to work and looking after young children but the long term physical 
and emotional effects impacted on ability.  
 
‘…my psychological problems are how do I live with not looking over my shoulder for this 
coming back?  And nobody could tell me it’s not going to come back.  I suppose that’s…  And 
the changes that it’s made to me as well, you know; people aren’t always happy if you don’t 
return to the same person that you were, and I’m not.’ (ID 06) 
 
DISCUSSION 
This study aimed to explore the experiences of women who received neo-adjuvant chemotherapy 
for breast cancer. Although neo-adjuvant chemotherapy is not as common as adjuvant 
chemotherapy, its use is increasing; to reportedly improve rates of breast conservation for women 
with operable disease (Herold & Marcom 2008). In this study it was apparent that information and 
support needs were not always addressed and there was room for improvement to meet the specific 
needs of this group.  
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Undergoing a toxic chemotherapy regime is accompanied by side effects for all oncology patients. 
However, for the women in this study, having chemotherapy prior to surgery brought an immediate 
transition from ‘well’ to ‘ill’. It is arguable that experiencing surgery first (while distressing and 
painful) does not have the same ‘illness’ connotations and allows patients to prepare for adjuvant 
chemotherapy. These relatively young participants also had to deal with caring responsibilities   
while trying to maintain their previous level of employment. Side effects were evident for all 
participants and were especially severe for the 11 women who required admission to a hospital 
Emergency Department and/or in-patient admission. A Spanish study recently reported a 10.5% 
admission rate to hospital for chemotherapy related symptoms for patients who had been 
diagnosed and treated for breast cancer(n=268); this was considered high (Baena-Canada,  
Estalella-Mendoza, Rosado-Varela, Exposito-Alvarez, Gonzalez-Guerrero, Diaz-Blanco, Cortes-
Carmona et al 2012.). Although sample size was small in the current study, 55% had a hospital 
admission for chemotherapy side effects. It is not clear if hospital admissions could have been 
prevented if patients were clear who to contact for information and support.  Those participants 
who were admitted to hospital encountered nurses on general hospital wards without cancer 
specific expertise and lacking understanding of the nature of chemotherapy side effects.  Earlier 
intervention by a specialist practitioner could arguably have saved the costs of in-patient admissions 
and saved patients the anxiety of feeling that HCPs lacked the expertise to deal with their specific 
problems.    
 
Participants described experiencing ‘chemo brain’ but also reported that HCPs were reluctant to 
acknowledge its existence. Recent research has produced interesting findings on ‘chemo brain’, 
arguing that it does exist (Holmes 2013, Hede 2008) and that chemotherapy (and other associated 
aspects of a cancer diagnosis) have a long lasting negative impact on cognitive function (Biglia, 
Bounous, Malabaila, Palmisano, Torta, D’Alonzo et al 2012; Koppelmans, Breteler, Boogerd 
Seynaeve, Gundy, Schagen 2012). However, not all women who undergo chemotherapy will 
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experience cognitive deficits. Other factors, such as self-perception of mental decline, levels of 
anxiety and depression and passive coping style may account for some degree of cognitive 
impairment (Biglia, Bounous, Malabaila, Palmisano, Torta, D’Alonzo et al 2012, Reid-Arndt & Cox 
2012). Cognitive dysfunction was a particularly distressing side effect for participants who had 
responsibilities for young children and wanted to return to work post treatment. If HCP’s do not 
acknowledge the existence of ‘chemo brain’ then it will be challenging at best for patients to obtain 
information and guidance on how to address the associated problems. Patients who perceive they 
have cognitive difficulties extending beyond the end of treatment may benefit from cognitive 
rehabilitation and coping strategies to improve memory (Hede 2008).  
 
Surgery is the mainstay of cancer treatment for many types of cancer at primary diagnosis and it was 
difficult for women in this study to retain the cancer tumour and live with it for a number of months. 
It was also difficult to explain the rationale for delaying surgery to family members and friends. The 
rationale that had been presented to participants was a need to reduce tumour size, but almost all 
(19/20) participants had mastectomy rather than lumpectomy and participants themselves were not 
clear why chemotherapy had therefore been recommended prior to surgery. A more detailed 
discussion on the rationale for neo-adjuvant chemotherapy is necessary so that women have a full 
understanding of why chemotherapy is given before, rather than after, surgery. There was little 
understanding that chemotherapy was a systemic treatment or the difference between ‘operable’ 
and ‘inoperable’ tumours.   
 
The extension of chemotherapy over a number of months allowed participants to shift from passive 
acceptance to a preference for active involvement in decision making. As the final cycles of 
chemotherapy were being administered and chemotherapy side effects were at their most toxic, 
participants knew that surgery was approaching. At this point more decisional support would have 
been welcomed. However, surgical options were limited. A recent French study reported that 
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women who receive neo-adjuvant chemotherapy do not necessarily undergo more conservative 
surgery with 60% of 210 women undergoing mastectomy (Dabakuyo, Arnaud, Maingon, Causeret, 
Coudert, Fumoleau et al 2013). In the current study, 95% (19/20) of participants had mastectomy, 
based on surgeon recommendation rather than patient preference.  However, a number of women 
had asserted their surgical preferences and requested bilateral mastectomy as they did not want to 
deal with a recurrence of cancer in the unaffected breast and did not want to go through a period of 
severe ‘illness’ again. It has been reported that more women are choosing bilateral mastectomy for 
unilateral breast cancer (Yao, Stewart, Winchester, Winchester 2010). Preference for bilateral 
mastectomy in younger women has been associated with higher neuroticism, perceived risk for 
contralateral breast cancer and lower preference for lumpectomy with  neuroticism viewed as an 
indicator of trait anxiety (King, O’Neill, Spellman, Peshkin, Valdimarsdottir, Willey et al 2013). Hence, 
it would seem vital to ensure effective communication about risk of recurrence and long term 
impact of surgical decisions in younger women undergoing neo-adjuvant chemotherapy as surgery 
approaches.   
 
There is arguably a need for more accurate information for individual women on the impact of 
surgical treatment and more understanding on the part of HCPs on the long term impact of a cancer 
diagnosis on women’s lives; for some women it was more important to reduce the risk of recurrence 
and/or further surgery than to conserve a healthy breast. However, the perception was that a 
bilateral mastectomy would reduce breast cancer recurrence. Contralateral prophylactic 
mastectomy greatly lowers the risk of developing cancer in the healthy breast, but there is no 
evidence of an increase in overall survival as an outcome (Tuttle, Habermann, Grund, Morris, Virnig 
2007).The risk of systemic metastases from the primary cancer often exceeds the risk of developing 
a contralateral breast cancer (Yi, Meric-Bernstam, Middleton, Arun, Bedrosian, Babiera et al 2009). It 
is not clear from the interview data if women understood the recurrence risk. It has been argued 
that any estimate of contralateral risk not based on genetic evidence of risk is likely to be an over-
22 
 
 
estimate (Wood 2009). To minimise the risk of regrets in women contemplating contralateral 
prophylactic mastectomy, it is important that women receive information on contralateral breast 
cancer risk, other alternatives, and a realistic expectation of the cosmetic outcome (Montgomery, 
Tran, Heelan, van Zee, Massie, Payne et al 1999). There is a key timepoint towards the end of 
chemotherapy, when surgery is approaching, when women would most benefit from this 
information. However, it is at this time that little information and support is available and contact 
with BCNs is limited. More formal contact with a HCP towards the end of chemotherapy treatment 
when women are engaged in thinking about surgical decisions would be helpful.  
 
Provision of information and support to women with breast cancer and their families is core to the 
role of the BCN (Jones, Leach, Chambers, Occhipinti 2010). It has been reported that BCN’s provide 
continuity of care and are available throughout the experience to discuss treatment options and 
concerns (Halkett, Arbon, Scutter, Borg 2006). This is not reflected in the present study, which 
showed a clear lack of continuity as participants embarked on their chemotherapy treatment; 
continuity was re-established at the time of surgery. An Australian study reported that BCN’s 
perceived themselves as important providers of psycho-social care and a link between patients and 
other services throughout the cancer journey; a role vital for the continuity of care (Jones, Leach, 
Chambers, Occhipinti 2010). In previous work it has been shown that BCN’s are important sources of 
information and support for women who have completed their treatment, with continuity of care 
and building a trusting  relationship shown to be important factors that patients value about contact 
with BCN’s (Beaver, Williamson, Chalmers 2010; Beaver, Tysver-Robinson, Campbell, Twomey, 
Williamson, Hindley et al 2009). However, breast cancer is the most common cancer and BCNs have 
extremely high case loads, necessitating a focus on newly diagnosed patients who need support to 
cope with the cancer diagnosis. However, most patients in this study did not receive the support of 
BCNs while they were undergoing neo-adjuvant chemotherapy. While it is probably not feasible for 
BCNs to provide continued support to all women undergoing neo-adjuvant chemotherapy, it is 
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important to acknowledge that physical, psychological and social needs are high during this period of 
time for both patients and their family members. Targeted communication at key time points (e.g. 
towards the end of chemotherapy) would have been beneficial for these women and may have 
prevented psychological problems escalating to a point of crisis.  
 
Family members (partners and children) were a major source of support but also needed support. It 
has been reported that carers’ emotional needs are similar to patients who undergo adjuvant 
chemotherapy. Carers go through a similar emotional journey in relation to the health-illness 
transition and provide support as a companion, protector, practical caregiver and advocate 
(Mcilfatrick, Sullivan, McKenna 2006). Hence, carers need to be acknowledged as valuable providers 
of support but also as needing support themselves to deal with the emotional impact of the 
diagnosis and treatment. Carers of women with breast cancer have been shown to have similar 
needs for information to those diagnosed and treated for breast cancer (Beaver & Witham 2007), 
indicating that discussions about care and treatment should involve close family members. As recall 
and retention of information are limited at the time of initial diagnosis, having family members in 
attendance at consultations and engaging with them as a unit of care may enable information to be 
better recalled and retained.   
 
Participants in this study appreciated support from those who would understand what they were 
experiencing. Participants were aware that they tended to be younger than other patients they 
encountered while undergoing chemotherapy.  It has been reported that younger women with 
breast cancer experience higher levels of distress, are more likely to be depressed and cope less well 
than older women (Cimprich, Ronis, Martinez-Ramos 2002;). A recent literature synthesis on the 
experiences, needs and concerns of younger women with breast cancer reported underdeveloped 
social support networks and concerns regarding reproduction, fertility and sexuality (Adams, 
McCann, Armes, Richardson, Stark, Watson et al 2011). Younger women have to balance their own 
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needs against the needs of their family, trying to protect children from the impact of the cancer and 
meet the financial demands of the household by maintaining paid employment (Adams, McCann, 
Armes, Richardson, Stark, Watson et al 2011). These age related issues were at the fore for 
participants in the current study. It is a cause for concern that women in the current study reported 
minimal contact with HCPs at a time of high need.           
 
Support from others going through the same experience was perceived as beneficial, whether face-
to-face or on-line. The use of the Internet as a form of information and support for people with 
cancer is becoming increasingly popular. A recent systematic review indicated that breast cancer 
survivors had a wide range of on-line support services available to them (Bender, Jimenez-
Marroquin, Ferris, Katz, Jadad 2013). However, a recent pilot study on unmoderated Internet based 
peer support for women with breast cancer indicates that this form of support may not necessarily 
be beneficial  (Salzer, Palmer, Kaplan, Brusilovskiy, Have, Hampshire et al 2010). Hence, it should not 
be assumed by HCPs that unmoderated on-line support will have a positive impact on patients’ 
psychological health, even if patients report satisfaction with such a resource, and should not 
assume that this form of support can replace that provided by HCP’s; more research is clearly 
needed in this developing area.  
  
While this study focused on patient experiences of neo-adjuvant chemotherapy, it could be argued 
that some of the issues and concerns raised are similar to patients undergoing chemotherapy post 
surgery. A study carried out in the UK identified the concerns of 33 women with breast, ovarian, 
cervical and uterine cancer (Farrell, Heaven, Beaver, Maguire 2005). Although it was not reported if 
the women in the Farrell et al (2005) study had received chemotherapy pre or post surgery, the 
primary concerns related to the current illness, inability to do things, treatment and the future. 
These concerns have some similarities to the present study findings. Mitchell (2007) explored the 
impact of chemotherapy treatment for 19 patients. Again, it was not reported if patients had 
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received chemotherapy per or post surgery but a number of the themes that emerged had 
resonance with our study findings. For example, patients in the Mitchell (2007) study indicated a 
desire for normality, concerns for young children and problems with concentration and memory.  
Hence, while some aspects of our findings are arguably unique to neo-adjuvant chemotherapy, such 
as living with the tumour and delays to surgery, other aspects may be common to all chemotherapy 
patients. More research is needed to clearly identify the needs of patients undergoing 
chemotherapy, both pre and post operatively.  
 
Limitations 
This was a small scale exploratory study and findings are not necessarily generalisable to other 
patients treated with neo-adjuvant chemotherapy for breast cancer. More work is needed in this 
area with a larger sample of women to confirm the generalisability of findings more broadly. The 
study was also limited in that it was conducted in the North West of England; sampling from more 
diverse geographical locations may have produced different findings. Study findings represent 
patient perceptions of their understandings. We do not know what participants were actually told 
about their cancer and the recommended treatment.       
 
We did not collect data on stage of disease or type of breast cancer from patient medical notes so 
we do not know how many of our sample had inflammatory breast cancer, the most aggressive form 
of breast cancer that tends to affect younger women (Anderson, Schairera, Chena, Hance, Levine 
2006). Given the young age of our sample it seems likely that some of these women had a diagnosis 
of inflammatory breast cancer; further work in this area should record histological details. The age of 
our sample was also a limitation in that older women were poorly represented. Hence, we were 
unable to explore the similarities and differences in views of younger and older participants.  
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CONCLUSIONS 
This small exploratory study provides important insights into the experiences of patients receiving 
neo-adjuvant chemotherapy for breast cancer. There were key time points at which information and 
support were most needed, but were lacking, particularly towards the end of chemotherapy. 
Continuity and support from BCNs is vital in developing services and interventions that will meet the 
complex needs of these patients and potentially prevent late referral to psychological services. 
Specialist BCNs have the ability to develop empathetic relationships with patients and the depth of 
experience, knowledge and skills to be able to answer the questions that most of these women had. 
Maintaining a relationship throughout neo-adjuvant chemotherapy would be ideal, although 
targeting key time points (e.g. towards the end of chemotherapy) would be highly beneficial.  
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Table 1. Characteristics of the study sample (n=20) 
Characteristic n % 
Marital Status 
Married/co-habiting 16 80 
Divorced/separated 1 5 
Never married 3 15 
Employment status 
Working full time 9 45 
Working part time 4 20 
Retired from work 2 10 
Not working due to illness 5 25 
Socio-economic group (based on occupation) 
Managers, directors and senior officials 3 15 
Professional occupations 3 15 
Associate professional and technical occupations 4 20 
Administrative and secretarial occupations 6 30 
Caring, leisure and other service occupations 2 10 
Elementary occupations 2 10 
Highest educational qualification 
No formal qualifications 2 10 
School leaving exams/certificate/diploma 10 50 
University degree 7 35 
Missing data 1 5 
Ethnic group 
White British 17 85 
Black African-Caribbean 2 10 
Indian 1 5 
Type of surgery received  
Bilateral Mastectomy 3 15 
Mastectomy 16 80 
Lumpectomy/wide local excision 1 5 
Reconstructive surgery 
Yes, completed 2 10 
No, but planned for future 4 20 
Uncertain at time of interview   1 5 
No, not planned 12 60 
Not applicable 1 5 
Radiotherapy  
Yes 20 100 
Required hospital A&E/in-patient admission during treatment 
Yes 11 55 
No 9 45 
Received psychological counselling 
Yes, for self only 8 40 
Yes, for self and children 1 5 
For children only 1 5 
No 10 50 
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Figure 1. Interview Guide 
 
 
Main areas to be explored: 
 
 Patients experiences of neo-adjuvant chemotherapy and the support they felt they needed 
at that time 
 
 Any concerns experienced during treatment (physical, psychological, social)  
 
Additional prompts: 
Did they get the support they needed? 
Who provided support? 
What could have been improved? 
What was done well? 
 
 Patient experiences of how information and choices about chemotherapy were 
communicated 
 
Additional prompts: 
Were choices presented?  
Who presented choices? 
If the patient was involved in the decision making process what information was 
useful?  
What could have been improved? 
What decision was made and what were the important considerations? 
  
 Information needs: what information was needed, sources of information   
 
 Patient views on the delay to local therapy (if relevant) 
 
Additional prompts: 
How was ‘delay’ perceived?  
Positive and negative perceptions  
Any raised anxieties? 
 
 Was any psychological distress experienced; referrals to psychological support services    
 
 Views on adequacy of service provision: helpful and unhelpful aspects, could any aspects be 
improved?  
 
 Any other important aspects of chemotherapy care and treatment that have not been 
discussed? 
 
 
